(IN BRIEF) Thousands of men with early-stage prostate cancer in England will now be offered stereotactic body radiotherapy, also known as stereotactic ablative radiotherapy, through the NHS after results from the PACE-B trial showed the treatment can be as effective … Read the full press release
Posted in Education, Government, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cancer care, cancer recurrence, cancer treatment, clinical research, Clinical Trials and Statistics Unit, early-stage prostate cancer, England, five-session treatment, gastrointestinal side effects, genital and urinary side effects, high-powered radiotherapy, hospital appointments, ICR, ICR and Royal Marsden Trial Supports Faster Radiotherapy Option for Prostate Cancer Patients, IMRT, intensity-modulated radiotherapy, localised prostate cancer, low-risk prostate cancer, medium-risk prostate cancer, NHS England, NHS England Approves SBRT for Eligible Men with Low and Medium-Risk Prostate Cancer, NHS radiotherapy centres, PACE-B trial, Phase III Trial, precision radiotherapy, Professor Emma Hall, Professor Nicholas van As, Professor Peter Johnson, prostate cancer, radiation beams, radiotherapy, randomised trial, SABR, SBRT, Shorter High-Powered Radiotherapy Course Set to Reduce Treatment Burden for Prostate Cancer Patients, stereotactic ablative radiotherapy, stereotactic body radiotherapy, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Thousands of Men in England to Benefit from More Precise Five-Visit Prostate Cancer Radiotherapy, treatment side effects, tumour targeting, United Kingdom
(IN BRIEF) The Institute of Cancer Research, London, has presented encouraging results from the phase Ib/II OrigAMI-4 clinical trial, showing that the targeted immunotherapy drug amivantamab shrank tumours in 42 per cent of patients with recurrent and/or metastatic head and … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, amivantamab, Amivantamab Demonstrates Encouraging Survival and Tumour Shrinkage Outcomes in Hard-to-Treat Head and Neck Cancer Patients, ASCO Annual Meeting, bispecific monoclonal antibody, cancer research, Carl Walsh, clinical trial, complete response, EGFR, head and neck squamous cell carcinoma, HNSCC, ICR, immunotherapy, Johnson & Johnson, Met, metastatic head and neck cancer, oncology, OrigAMI-4, OrigAMI-5, outpatient cancer treatment, partial response, phase Ib II trial, Phase III Trial, platinum-based chemotherapy, Professor Kevin Harrington, Professor Kristian Helin, recurrent head and neck cancer, Subcutaneous Injection, targeted cancer treatment, Targeted Immunotherapy Injection Shows Strong Clinical Activity in Patients with Treatment-Resistant Head and Neck Cancer, The Institute of Cancer Research and Royal Marsden Team Advance Clinical Evidence for Injectable Head and Neck Cancer Treatment, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, treatment-resistant cancer, tumour shrinkage
(IN BRIEF) ISS has expanded its partnership with the Fulham Road Collaborative in the UK, which includes Chelsea and Westminster Hospital NHS Foundation Trust and The Royal Marsden NHS Foundation Trust, in a contract valued at around DKK 100 million … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Technology, United Kingdom
Tagged and operational integration, Care Quality Commission, catering, Chelsea and Westminster Hospital NHS Foundation Trust, contract expansion, facility management, Fulham Road Collaborative, healthcare services, hospital operations, integrated services, ISS A/S, ISS secures major UK hospital services contract expansion focused on innovation, NHS, patient care, patient experience, portering, Scott Davies, SECURITY, The Royal Marsden NHS Foundation Trust, UK healthcare sector
(IN BRIEF) The Institute of Cancer Research has welcomed Sutton Council’s approval of ambitious plans led by Aviva Capital Partners and Socius to create around one million square feet of new life-sciences research and laboratory space across a 12-acre site … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Insurance, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aviva Capital Partners, cancer research, Daniel May, economic growth, high-skilled jobs, ICR, ICR Welcomes Approval of New One-Million-Square-Foot Life-Sciences Campus at The London Cancer Hub, Innovation Gateway, Institute of Cancer Research, Kristian Helin, laboratory space, life sciences, London Borough of Sutton, research and development, science infrastructure, Socius, Sophie White, Sutton, The London Cancer Hub, The Royal Marsden NHS Foundation Trust
(IN BRIEF) Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have developed AI software that automates the complex interpretation of whole-body diffusion-weighted MRI scans, which are increasingly used to evaluate advanced prostate cancer. The … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI MRI prostate cancer, AI-driven MRI software could streamline metastatic tumour evaluation and support next-generation precision oncology, anatomical segmentation, Computer Methods and Programs in Biomedicine, Dr Antonio Candito, Dr Matthew Blackledge, lesion detection, metastatic prostate cancer, NIHR Invention for Innovation, personalised oncology, Physics in Medicine & Biology, precision cancer care, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, tumour burden quantification, WB-DWI, whole-body diffusion-weighted MRI
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?